SCHEMBL1820973

SCHEMBL1820973

COC(=O)C1SC=CC1=O

nearest known ligand 0.34

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
DNTT P04053 2/20 0.34
POLB P06746 2/20 0.33
POLA1 P09884 1/20 0.33
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 1/20 0.32
BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28422694 0.76
SCHEMBL6015239 0.74
SCHEMBL28228071 0.71 KMT2A (0.31) KMT2AALDH1A1BRD4
SCHEMBL8887916 0.68 KMT2A (0.35) DNTTPOLBPOLA1KMT2AALDH1A1
SCHEMBL17322451 0.67 ALDH1A1 (0.40) DNTTPOLBPOLA1KMT2AALDH1A1
SCHEMBL2761099 0.67 BRD4 (0.39) POLBKMT2AALDH1A1BRD4
SCHEMBL10919849 0.60 TDP1 (0.34) POLBALDH1A1
SCHEMBL13911364 0.60 ALDH1A1 (0.35) DNTTPOLBPOLA1KMT2AALDH1A1
SCHEMBL3058001 0.60 KMT2A (0.35) KMT2AALDH1A1BRD4
SCHEMBL7929530 0.60 DNTT (0.37) DNTTPOLBPOLA1ALDH1A1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8471010-B2 Synthesis of dihydrothieno[3,2-d]pyrimidine diols BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-25 US disclosed
EP-2315755-B1 SYNTHESIS OF DIHYDROTHIENO[3,2-d]PYRIMIDINE DIOLS AND SIMILAR PYRIMIDINE DIOLS BOEHRINGER INGELHEIM INT (DE) 2012-08-08 EP disclosed
US-20110130563-A1 SYNTHESIS IF DIHYDROTHIENO[3,2-D]PYRIMIDINE DIOLS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-02 US disclosed
EP-2315755-A2 SYNTHESIS OF DIHYDROTHIENO[3,2-d]PYRIMIDINE DIOLS AND SIMILAR PYRIMIDINE DIOLS Boehringer Ingelheim International GmbH (DE) 2011-05-04 EP disclosed
WO-2009140127-A2 SYNTHESIS OF DIHYDROTHIENO[3,2-d]PYRIMIDINE DIOLS AND SIMILAR PYRIMIDINE DIOLS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-19 WO disclosed
US-5541202-A New leukotriene-B4 Antagonists and their use as pharmaceutical agents SCHERING AKTIENGESELLSCAFT (DE) 1996-07-30 US disclosed
US-4143050-A MANUFACTURE OF 3-HALOSULFONYLTHIOPHENE-CARBOXYLIC ACID COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 1979-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130563-A1 SYNTHESIS IF DIHYDROTHIENO[3,2-D]PYRIMIDINE DIOLS DPYD, DHODH, PDE4B DNTT 144/4885POLB 457/4885POLA1 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.